Skip to main content
menu

Frisch Lab

Research Description

Using a translational approach, the Frisch lab is interested in understanding the microenvironmental factors that support hematopoietic stem cells (HSCs) in the bone marrow during health and disease. Through this research we aim to identify novel therapeutic targets in malignant hematopoiesis, such as acute myeloid leukemia (AML).

Current research projects in the lab are focused on alterations of the bone marrow microenvironment (BMME) induced by myeloid malignancies. This research has led to the identification of the chemokine CCL3 as a key factor in leukemogenesis in murine models. Future interests are in further characterization of the interactions between malignant hematopoiesis and the BMME, with the ultimate goal of the translation of novel therapeutic targets to clinical use.


widget-a7dbafb6-e1b

Benjamin J. Frisch, Ph.D.

Benjamin J. Frisch, Ph.D.
Principal Investigator

Projects

  • Developing an Organ-On-Chip Model of the Bone Marrow to Study AML
  • Targeting CCL3 Signaling as a Therapeutic Strategy for AML
  • Characterizing T Cell Functions in Acute Myeloid Leukemia (AML) Bone Marrow Microenvironment (BMME)
View All Projects

Publications

Ackun-Farmmer, Marian A., Hanan Alwaseem, Michele Counts, Andrew Bortz, Simone Giovani, Benjamin J. Frisch, Rudi Fasan, and Danielle S. W. Benoit. 2022. “Nanoparticle-Mediated Delivery of Micheliolide Analogs to Eliminate Leukemic Stem Cells in the Bone Marrow.” Advanced Therapeutics 5 (1): 2100100. https://doi.org/10.1002/adtp.202100100.

Ackun-Farmmer, Marian A., Celia A. Soto, Maggie L. Lesch, Daniel Byun, Lila Yang, Laura M. Calvi, Danielle S. W. Benoit, and Benjamin J. Frisch. 2021. “Reduction of Leukemic Burden via Bone-Targeted Nanoparticle Delivery of an Inhibitor of C-Chemokine (C-C Motif) Ligand 3 (CCL3) Signaling.” The FASEB Journal 35 (4): e21402. https://doi.org/10.1096/fj.202000938RR.

Frisch, Benjamin, Omar Aljitawi, and Brian Marples. 2024. “The Combination of Hbo and ACE-I Significantly Reduces EPO for 72 Hours Following Hbo and Improves Bone Marrow Homing of HSPCs.” Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy 30 (2): S62. https://doi.org/10.1016/j.jtct.2023.12.098.

View All Publications

News

widget-191a9f5e-667

June 17, 2025
Jordyn Presented her Research at the 2024-2025 URMC PREP Program Special Symposium

June 9, 2025
Azmeer and Ben went to the Microphysiological Systems World Summit in Brussels

June 5, 2025
The Lab Welcomes Owen Hodges as this Year’s SURF Summer Student

View All News

Contact Us

Frisch Lab
Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642